摘要
目的：探讨前列地尔对急性冠状动脉综合征患者血清心型脂肪酸结合蛋白（ H-FABP）和基质金属蛋白酶-9（MMP-9）的影响。方法98例急性冠状动脉综合征患者随机分为两组，对照组49例采用常规治疗，观察组49例在常规治疗的基础上加用前列地尔，两组共治疗14 d。治疗前后测定血清H-FABP和MMP-9。观察两组患者出院后30 d、3个月和6个月主要终点事件的发生率。结果对照组出院后30 d、3个月、6个月时主要终点事件发生例数为5、10、18例，观察组为1、5、8例，观察组均明显少于对照组（ P均﹤0.01）。两组治疗后患者血清H-FABP和MMP-9均有明显降低（P﹤0.01），且与对照组比较，观察组治疗后降低更明显（P﹤0.05）。结论前列地尔可以明显减少急性冠状动脉综合征患者血清H-FABP和MMP-9的表达。
Objective To study the effect of alprostadil on serum heart-type fatty acid binding protein（ H-FABP）and matrix metalloproteinase-9（ MMP-9 ）in patients with acute coronary syndrome. Methods Ninety-eight patients with acute coronary syndrome were randomly divided into two groups, the control group（49 cases）and the observation group（49 cases）. The patients in the control group were treated by the conventional treatment,while the patients in the observation group were treated by the conventional treatment plus alprostadil. They were treated for 14 days. Serum H-FABP and MMP-9 levels were detected before and after treatment. The incidence of primary endpoint were observed after 30 d, 3 months and 6 months discharged from hospital. Results In the control group,after 30 d,3 months, 6 months discharged from hospital,the primary endpoint occurred cases was 5,10,18. In the observation group,after 30 d,3 months,6 months discharged from hospital,the primary endpoint occurred cases was 1,5,8. There were significant differences（P ﹤0. 01）. After treatment,the serum H-FABP and MMP-9 evels were significantly lower（P﹤0. 01）,compared with the control group,the levels in observation group decreased more significantly after treatment（ P﹤0. 05 ）. Conclusions Alprostadil can decrease the serum H-FABP and MMP-9 levels in patients with acute coronary syndrome.
出处
《中国实用医刊》
2014年第16期44-46,共3页
Chinese Journal of Practical Medicine
